New Crown Vaccine Victory! WHO Listed AstraZeneca AZD1222 in Emergency Use List: Conventional Cold Storage, 2 Dose Immunization, Non-Profit Supply Worldwide -AstraZeneca Zone-Biology Valley

02/16/2021 Health, World



[ad_1]

Feb 16, 2021 News / Bio Valley BIOON / – At present, the new corona pneumonia epidemic abroad is still spreading rapidly. According to Baidu’s new coronavirus pneumonia epidemic real-time Big Data report, as of 10 p.m. on February 16, 2021, there have been more than 100 million confirmed cases (109.76 million) across the world and more than 2.42 million deaths.
AstraZeneca recently issued an announcement stating that the COVID-19 Vaccine AstraZeneca adenovirus vaccine (formerly AZD1222) developed by the company and the University of Oxford has been included on the Emergency Use List (EUL) of the World Health Organization (WHO). vaccinate people 18 years of age and older (including those 65 and older) to prevent COVID-19. It is worth mentioning that,COVID-19 Vaccine AstraZeneca vaccine can be stored, transported and handled under conventional refrigeration conditions (2-8 ° C / 36-46 ° F) for at least 6 months and used in existing medical settings.

The authorization of the AstraZeneca vaccine of the COVID-19 vaccine produced by AstraZeneca and the COVISHIELD vaccine produced by the Serological Institute of India (SII) (the trade name of the AstraZeneca COVID-19 vaccine in India) will allow the world survive the COVID 19 Pandemic. Get this vaccine.

EUL allows 2 doses of vaccine every 4-12 weeks. Clinical trials have shown the program to be safe and effective in preventing symptomatic COVID-19. 14 days after the second injection, there were no serious cases or hospitalizations. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends that the injection interval be 8 to 12 weeks. Furthermore, they also recommend the use of this vaccine in countries where newer variants (including South African B1.351 variants) are endemic.

AstraZeneca is committed to providing its COVID-19 vaccine to as many countries as possible during the pandemic without realizing any benefit. In June 2020, the company announced that it had entered into a sublicense agreement with SII to produce and supply up to 1 billion doses of vaccines to low- and middle-income countries.

AstraZeneca is the first global pharmaceutical company to join COVAX (WHO’s new coronary pneumonia vaccine implementation plan) in June 2020. This global mechanism is working hard to accelerate the development and production of new COVID tools. -19, and to allow all participating countries, regardless of income level, to have fair access to these tools worldwide.

Now, AstraZeneca and SII will cooperate with the COVAX Facility to begin supplying vaccines worldwide, most of which will be shipped to low- and middle-income countries as soon as possible. In the first half of 2021, COVAX is expected to provide more than 300 million doses of vaccine to 145 countries. These doses will be distributed equitably according to the COVAX distribution framework.

Pascal Soriot, CEO of AstraZeneca, said: “Today’s approval recognizes that this vaccine can be used to help protect the world’s population, including the elderly over 65, as well as in countries where different variants of SARS-CoV- 2 are endemic – a big step towards ensuring global access to our vaccines and helping us meet our public health commitment to achieve widespread, fair and unprofitable access to vaccines during a pandemic. “

Adar Poonawalla, Executive Director of the Serum Institute of India (SII), said: “We have been waiting for this final milestone. I am delighted and satisfied that with the WHO EUL, we can immediately start marketing in Africa and other countries. The vaccines they are delivered to low- and middle-income countries. Countries with large populations must be protected as soon as possible. “

The COVID-19 AstraZeneca vaccine (formerly AZD1222) was invented by the University of Oxford and its spin-off Vaccitech. It uses a replication-deficient chimpanzee virus vector based on a weakened version of the common cold virus (adenovirus), which causes infection in chimpanzees and contains the genetic material for the SARS-CoV-2 virus spike protein. After vaccination, a spike protein is produced on the surface, which stimulates the immune system to attack the SARS-CoV-2 virus.
The approval by the World Health Organization (WHO) is based on a meta-analysis of the efficacy of 11,636 participants aged 18 years and over. These participants came from phase III trials conducted by the University of Oxford in the United Kingdom and Brazil, accumulating 131 cases of COVID-19 infection symptoms.Overall safety is based on four tests conducted in the UK, Brazil and South Africa.Clinical trialsAn interim analysis of the aggregated data included 23,745 participants aged 18 years and over.AstraZeneca’s COVID-19 vaccine is well tolerated and there have been no serious vaccine-related safety incidents. Participants come from different ethnic and geographic groups, are healthy, or have stable underlying diseases.

In addition to the program run by the University of Oxford, AstraZeneca is also conducting large-scale trials in the United States and around the world. The University of Oxford and AstraZeneca are expected to enroll up to 60,000 subjects worldwide.

AstraZeneca’s COVID-19 vaccine has obtained conditional marketing authorization or emergency use in more than 50 countries. Now, the WHO EUL will accelerate access to this vaccine in up to 145 countries through the COVAX facility.(Bioon.com)

原文 出处 ： AstraZeneca COVID-19 vaccine licensed for emergency use by the World Health Organization

[ad_2]
Designed by Tricksfast Solutions
© Copyright 2024, All Rights Reserved